Do mycophenolic acid and gliotoxin suppress immune function?

Mycophenolic acid (MPA) and gliotoxin have credible immunosuppressive biology, but laboratory detection—particularly in urine—cannot be equated with clinically important immune impairment.

Clinical and experimental evidence

• MPA is an established pharmacologic immunosuppressant. In primary human peripheral-blood mononuclear cells, it inhibited stimulated T- and B-cell proliferation with approximate IC50 values of 89 ± 52 nM and 87 ± 63 nM, respectively. In transplant regimens, MPA reduced acute rejection/treatment failure versus azathioprine, although higher doses increased opportunistic and CMV infections.
• Gliotoxin suppresses immune functions in experimental systems: macrophage phagocytosis at approximately 20–50 ng/mL, neutrophil phagocytosis at 30–100 ng/mL, and human lymphocyte growth by about 21% at 25 ng/mL to 87% at 200 ng/mL. It can also reduce macrophage TNF-α and IL-6 responses. At 0.3–3 µM, however, apoptosis/cytotoxicity may contribute to apparent suppression.

Mechanistic context

• MPA reversibly, noncompetitively inhibits IMPDH, particularly IMPDH2 in activated lymphocytes, depleting GMP/GTP/dGTP needed for DNA synthesis. Guanosine reversal of the cellular effect supports this mechanism.
• Gliotoxin impairs innate defense partly through disruption of PtdIns(3,4,5)P₃-dependent actin protrusions, reducing phagocytic target binding/internalization; altered NF-κB signaling and cytokine responses provide additional mechanistic support.

Clinical interpretation

• A toxin-panel result does not provide a validated threshold for immune suppression, infection risk, or impaired host defense, nor does it establish source, systemic/internal dose, or duration of exposure.
• In a 77-year-old, clinically meaningful concern should be corroborated with infection history, CBC with differential, quantitative immunoglobulins when indicated, lymphocyte subsets and/or functional antibody responses, medication review, and assessment for protein loss or systemic disease.

Bottom line

• Detection is an exposure signal, not proof of clinically significant immune suppression. MPA and gliotoxin warrant contextual clinical assessment, not inference of immune toxicity from the panel alone.